Dr Laura Moffitt

Moffitt LR, Karimnia N, Wilson AL, Stephens AN, Ho GY, Bilandzic M (2024) Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer. Curr Oncol 31:8023-8038.

Wilson AL, Moffitt LR, Doran BR, Basri B, Do J, Jobling TW, Plebanski M, Stephens AN, Bilandzic M (2024) Leader cells promote immunosuppression to drive ovarian cancer progression in vivo. Cell Rep 43:114979.

Doran BR, Moffitt LR, Wilson AL, Stephens AN, Bilandzic M (2024) Leader Cells: Invade and Evade-The Frontline of Cancer Progression. Int J Mol Sci 25:10554.

Wilson AL, Moffitt LR, Wilson KL, Bilandzic M, Wright MD, Gorrell MD, Oehler MK, Plebanski M, Stephens AN (2021) DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model. Cancers (Basel) 13:487.

Moffitt LR, Bilandzic M, Wilson AL, Chen Y, Gorrell MD, Oehler MK, Plebanski M, Stephens AN (2020) Hypoxia Regulates DPP4 Expression, Proteolytic Inactivation, and Shedding from Ovarian Cancer Cells. Int J Mol Sci 21:8110.

Moffitt L, Karimnia N, Stephens A, Bilandzic M (2019) Therapeutic Targeting of Collective Invasion in Ovarian Cancer. Int J Mol Sci 20:1466.

Wilson AL, Wilson KL, Bilandzic M, Moffitt LR, Makanji M, Gorrell MD, Oehler MK, Rainczuk A, Stephens AN, Plebanski M (2018) Non-Invasive Fluorescent Monitoring of Ovarian Cancer in an Immunocompetent Mouse Model. Cancers (Basel) 11:32.

Wilson AL, Moffitt LR, Duffield N, Rainczuk A, Jobling TW, Plebanski M, Stephens AN (2018) Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 27:183-192.